Skip to main content
Top

2018 | OriginalPaper | Chapter

5. Silica-Based Polymeric Gels as Platforms for Delivery of Phosphonate Pharmaceutics

Authors : Konstantinos E. Papathanasiou, Maria Vassaki, Argyro Spinthaki, Argyri Moschona, Konstantinos D. Demadis

Published in: Polymer Gels

Publisher: Springer Singapore

Activate our intelligent search to find suitable subject content or patents.

search-config
loading …

Abstract

This chapter focuses on polymeric gel drug delivery systems used for initial immobilization and subsequent controlled release of active pharmaceutical ingredients. The primary focus is on phosphonate-based drugs, which are extensively used for a variety of medicinal applications and pathological conditions. Their most recognizable use is for osteoporosis drugs with the common names: medronate, chlodronate, etidronate, alendronate, zoledronate, obadronate, ibandronate, neridronate, etc. Herein, we present a concise literature overview of this research field, presenting research results on immobilization of phosphonates onto silica-based polymeric gels, with the goal to achieve controlled release of these ingredients into biological fluids.

Dont have a licence yet? Then find out more about our products and how to get one now:

Springer Professional "Wirtschaft+Technik"

Online-Abonnement

Mit Springer Professional "Wirtschaft+Technik" erhalten Sie Zugriff auf:

  • über 102.000 Bücher
  • über 537 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Finance + Banking
  • Management + Führung
  • Marketing + Vertrieb
  • Maschinenbau + Werkstoffe
  • Versicherung + Risiko

Jetzt Wissensvorsprung sichern!

Springer Professional "Technik"

Online-Abonnement

Mit Springer Professional "Technik" erhalten Sie Zugriff auf:

  • über 67.000 Bücher
  • über 390 Zeitschriften

aus folgenden Fachgebieten:

  • Automobil + Motoren
  • Bauwesen + Immobilien
  • Business IT + Informatik
  • Elektrotechnik + Elektronik
  • Energie + Nachhaltigkeit
  • Maschinenbau + Werkstoffe




 

Jetzt Wissensvorsprung sichern!

Literature
go back to reference Balas F, Manzano M, Horcajada P, Vallet-Regí M (2006) Confinement and controlled release of bisphosphonates on ordered mesoporous silica-based materials. J Am Chem Soc 128:8116–8117CrossRefPubMed Balas F, Manzano M, Horcajada P, Vallet-Regí M (2006) Confinement and controlled release of bisphosphonates on ordered mesoporous silica-based materials. J Am Chem Soc 128:8116–8117CrossRefPubMed
go back to reference Belton DJ, Patwardhan SV, Perry CC (2005) Spermine, spermidine and their analogues generate tailored silicas. J Mater Chem 15:4629–4638CrossRef Belton DJ, Patwardhan SV, Perry CC (2005) Spermine, spermidine and their analogues generate tailored silicas. J Mater Chem 15:4629–4638CrossRef
go back to reference Belton DJ, Patwardhan SV, Annenkov VV, Danilovtseva EN, Perry CC (2008) From biosilicification to tailored materials: optimizing hydrophobic domains and resistance to protonation of polyamines. Proc Natl Acad Sci USA 105:5963–5968CrossRefPubMedPubMedCentral Belton DJ, Patwardhan SV, Annenkov VV, Danilovtseva EN, Perry CC (2008) From biosilicification to tailored materials: optimizing hydrophobic domains and resistance to protonation of polyamines. Proc Natl Acad Sci USA 105:5963–5968CrossRefPubMedPubMedCentral
go back to reference Binauld S, Stenzel MH (2013) Acid-degradable polymers for drug delivery: a decade of innovation. Chem Commun 49:2082–2102CrossRef Binauld S, Stenzel MH (2013) Acid-degradable polymers for drug delivery: a decade of innovation. Chem Commun 49:2082–2102CrossRef
go back to reference Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, LoRusso P, Ma P, Ravera C, Deckert F, Schran H, Seaman J, Skerjanec A (2002) Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 42:1228–1236CrossRefPubMed Chen T, Berenson J, Vescio R, Swift R, Gilchick A, Goodin S, LoRusso P, Ma P, Ravera C, Deckert F, Schran H, Seaman J, Skerjanec A (2002) Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases. J Clin Pharmacol 42:1228–1236CrossRefPubMed
go back to reference Chong ASM, Zhao XS (2003) Functionalization of SBA-15 with APTES and characterization of functionalized materials. J Phys Chem B 107:12650–12657CrossRef Chong ASM, Zhao XS (2003) Functionalization of SBA-15 with APTES and characterization of functionalized materials. J Phys Chem B 107:12650–12657CrossRef
go back to reference Coradin T, Eglin D, Livage J (2004) The silicomolybdic acid spectrophotometric method and its application to silicate/biopolymer interaction studies. Spectroscopy 18:567–576CrossRef Coradin T, Eglin D, Livage J (2004) The silicomolybdic acid spectrophotometric method and its application to silicate/biopolymer interaction studies. Spectroscopy 18:567–576CrossRef
go back to reference Cremers SC, Pillai G, Papapoulos SE (2005) Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet 44:551–570CrossRefPubMed Cremers SC, Pillai G, Papapoulos SE (2005) Pharmacokinetics/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis. Clin Pharmacokinet 44:551–570CrossRefPubMed
go back to reference Demadis KD (2008) Silica scale inhibition relevant to desalination technologies: progress and recent developments. In: Delgado DJ, Moreno P (eds) Desalination research progress. Nova Science Publishers, Inc., New York, pp 249–259 Demadis KD (2008) Silica scale inhibition relevant to desalination technologies: progress and recent developments. In: Delgado DJ, Moreno P (eds) Desalination research progress. Nova Science Publishers, Inc., New York, pp 249–259
go back to reference Dunford JE, Thomspson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ (2001) Structure-activity relationships for inhibition of farnesyl disphosphate syntase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharm Exp Ther 296:235–242 Dunford JE, Thomspson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ (2001) Structure-activity relationships for inhibition of farnesyl disphosphate syntase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharm Exp Ther 296:235–242
go back to reference Ehrlich H, Demadis KD, Koutsoukos PG, Pokrovsky O (2010) Modern views on desilicification: biosilica and abiotic silica dissolution in natural and artificial environments. Chem Rev 110:4656–4689CrossRefPubMed Ehrlich H, Demadis KD, Koutsoukos PG, Pokrovsky O (2010) Modern views on desilicification: biosilica and abiotic silica dissolution in natural and artificial environments. Chem Rev 110:4656–4689CrossRefPubMed
go back to reference Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RG, Rodan GA, Reszka AA (1999) Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption and kinase activation in vitro. Proc Natl Acad Sci USA 96:133–138CrossRefPubMedPubMedCentral Fisher JE, Rogers MJ, Halasy JM, Luckman SP, Hughes DE, Masarachia PJ, Wesolowski G, Russell RG, Rodan GA, Reszka AA (1999) Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption and kinase activation in vitro. Proc Natl Acad Sci USA 96:133–138CrossRefPubMedPubMedCentral
go back to reference Fleisch H, Reszka A, Rodan G, Rogers G (2002) Bisphosphonates: mechanisms of action. In: Bilezikian JP, Raisz LG, Rodan GA (eds) Principles of bone biology. Academic Press, San Diego, pp 1361–1385 Fleisch H, Reszka A, Rodan G, Rogers G (2002) Bisphosphonates: mechanisms of action. In: Bilezikian JP, Raisz LG, Rodan GA (eds) Principles of bone biology. Academic Press, San Diego, pp 1361–1385
go back to reference Francis MD, Fogelman I (1987) 99 mTc diphosphonate uptake mechanism on bone. In: Fogelman I (ed) Bone scanning in clinical practice. Springer, New York, pp 7–17CrossRef Francis MD, Fogelman I (1987) 99 mTc diphosphonate uptake mechanism on bone. In: Fogelman I (ed) Bone scanning in clinical practice. Springer, New York, pp 7–17CrossRef
go back to reference Francis MD, Graham R, Russell RGG, Fleisch H (1969) Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 165:1264–1266CrossRefPubMed Francis MD, Graham R, Russell RGG, Fleisch H (1969) Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science 165:1264–1266CrossRefPubMed
go back to reference Frith JC, Mönkkönen J, Blackburn GM, Russell RGG, Rogers MJ (1997) Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(β, γ-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 12:1358–1367CrossRefPubMed Frith JC, Mönkkönen J, Blackburn GM, Russell RGG, Rogers MJ (1997) Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′-(β, γ-dichloromethylene) triphosphate, by mammalian cells in vitro. J Bone Miner Res 12:1358–1367CrossRefPubMed
go back to reference Fujisaki J, Tokunaga Y, Takahashi T, Hirose T, Shimojo F, Kagayama A, Hata T (1995) Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. I: synthesis and in vivo characterization of osteotropic carboxyfluorescein. J Drug Target 3:273–282CrossRefPubMed Fujisaki J, Tokunaga Y, Takahashi T, Hirose T, Shimojo F, Kagayama A, Hata T (1995) Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. I: synthesis and in vivo characterization of osteotropic carboxyfluorescein. J Drug Target 3:273–282CrossRefPubMed
go back to reference Fujisaki J, Tokunaga Y, Sawamoto T, Takahashi T, Kimura S, Shimojo F, Hata T (1996a) Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. III: pharmacokinetics and targeting characteristics of osteotropic carboxyfluorescein. J Drug Target 4:117–123CrossRefPubMed Fujisaki J, Tokunaga Y, Sawamoto T, Takahashi T, Kimura S, Shimojo F, Hata T (1996a) Osteotropic drug delivery system (ODDS) based on bisphosphonic prodrug. III: pharmacokinetics and targeting characteristics of osteotropic carboxyfluorescein. J Drug Target 4:117–123CrossRefPubMed
go back to reference Fujisaki J, Tokunaga Y, Takahashi T, Murata S, Shimojo F, Hata T (1996b) Physicochemical characterization of bisphosphonic carboxyfluorescein for osteotropic drug delivery. J Pharm Pharmacol 48:798–800CrossRefPubMed Fujisaki J, Tokunaga Y, Takahashi T, Murata S, Shimojo F, Hata T (1996b) Physicochemical characterization of bisphosphonic carboxyfluorescein for osteotropic drug delivery. J Pharm Pharmacol 48:798–800CrossRefPubMed
go back to reference Giger EV, Castagner B, Leroux J-C (2013) Biomedical applications of bisphosphonates. J Control Release 167:175–188CrossRefPubMed Giger EV, Castagner B, Leroux J-C (2013) Biomedical applications of bisphosphonates. J Control Release 167:175–188CrossRefPubMed
go back to reference Gil L, Han Y, Opas EE, Rodan GA, Ruel R, Seedor JG, Tyler PC, Young RN (1999) Prostaglandin E2–bisphosphonate conjugates: potential agents for treatment of osteoporosis. Bioorg Med Chem 7:901–919CrossRefPubMed Gil L, Han Y, Opas EE, Rodan GA, Ruel R, Seedor JG, Tyler PC, Young RN (1999) Prostaglandin E2–bisphosphonate conjugates: potential agents for treatment of osteoporosis. Bioorg Med Chem 7:901–919CrossRefPubMed
go back to reference Gittens SA, Bansal G, Zernicke RF, Uludag H (2005) Designing proteins for bone targeting. Adv Drug Deliv Rev 57:1011–1036CrossRefPubMed Gittens SA, Bansal G, Zernicke RF, Uludag H (2005) Designing proteins for bone targeting. Adv Drug Deliv Rev 57:1011–1036CrossRefPubMed
go back to reference Golomb G, Dixon M, Smith MS, Schoen FJ, Levy RJ (1987) Controlled-release drug delivery of diphosphonates to inhibit bioprosthetic heart valve calcification: release rate modulation with silicone matrices via drug solubility and membrane coating. J Pharm Sci 76:271–276CrossRefPubMed Golomb G, Dixon M, Smith MS, Schoen FJ, Levy RJ (1987) Controlled-release drug delivery of diphosphonates to inhibit bioprosthetic heart valve calcification: release rate modulation with silicone matrices via drug solubility and membrane coating. J Pharm Sci 76:271–276CrossRefPubMed
go back to reference Gommes C, Blacher S, Goderis B, Pirard R, Heinrichs B, Alie C, Pirard JP (2004) In situ SAXS analysis of silica gel formation with an additive. J Phys Chem B 108:8983–8991CrossRef Gommes C, Blacher S, Goderis B, Pirard R, Heinrichs B, Alie C, Pirard JP (2004) In situ SAXS analysis of silica gel formation with an additive. J Phys Chem B 108:8983–8991CrossRef
go back to reference Hengst V, Oussoren C, Kissel T, Storm G (2007) Bone targeting potential of bisphosphonate-targeted liposomes. Preparation, characterization and hydroxyapatite binding in vitro. Int J Pharm 331:224–227CrossRefPubMed Hengst V, Oussoren C, Kissel T, Storm G (2007) Bone targeting potential of bisphosphonate-targeted liposomes. Preparation, characterization and hydroxyapatite binding in vitro. Int J Pharm 331:224–227CrossRefPubMed
go back to reference Hirabayashi H, Takahashi T, Fujisaki J, Masunaga T, Sato S, Hiroi J, Tokunaga Y, Kimura S, Hata T (2001) Bone specific delivery and sustained release of diclofenac, a non- steroidal anti-inflammatory drug, via bisphosphonic prodrug based on osteotropic drug delivery system (ODDS). J Control Release 70:183–191CrossRefPubMed Hirabayashi H, Takahashi T, Fujisaki J, Masunaga T, Sato S, Hiroi J, Tokunaga Y, Kimura S, Hata T (2001) Bone specific delivery and sustained release of diclofenac, a non- steroidal anti-inflammatory drug, via bisphosphonic prodrug based on osteotropic drug delivery system (ODDS). J Control Release 70:183–191CrossRefPubMed
go back to reference Hosain F, Spencer RP, Couthon HM, Sturtz GL (1996) Targeted delivery of antineoplastic agent to bone: biodistribution studies of technetium-99m-labeled gembisphosphonate conjugate of methotrexate. J Nucl Med 37:105–107PubMed Hosain F, Spencer RP, Couthon HM, Sturtz GL (1996) Targeted delivery of antineoplastic agent to bone: biodistribution studies of technetium-99m-labeled gembisphosphonate conjugate of methotrexate. J Nucl Med 37:105–107PubMed
go back to reference Hughes LG, Vick TA, Wang JH (2004) Coated Implants. European Patent 1250164 Hughes LG, Vick TA, Wang JH (2004) Coated Implants. European Patent 1250164
go back to reference Kennedy JH (1997) HPLC purification of pergolide using silica gel. Org Process Res Dev 1:68–71CrossRef Kennedy JH (1997) HPLC purification of pergolide using silica gel. Org Process Res Dev 1:68–71CrossRef
go back to reference Lehenkari PP, Kellinsalmi M, Näpänkangas JP, Ylitalo KV, Mönkkönen J, Rogers MJ, Azhayev A, Väänänen HK, Hassinen IE (2002) Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol 61:1255–1262CrossRefPubMed Lehenkari PP, Kellinsalmi M, Näpänkangas JP, Ylitalo KV, Mönkkönen J, Rogers MJ, Azhayev A, Väänänen HK, Hassinen IE (2002) Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite. Mol Pharmacol 61:1255–1262CrossRefPubMed
go back to reference Levy RJ, Wolfrum J, Schoen FJ, Hawley MA, Lund SA, Langer R (1985) Inhibition of calcification of bioprosthetic heart valves by local controlled-release diphosphonate. Science 228:190–192CrossRefPubMed Levy RJ, Wolfrum J, Schoen FJ, Hawley MA, Lund SA, Langer R (1985) Inhibition of calcification of bioprosthetic heart valves by local controlled-release diphosphonate. Science 228:190–192CrossRefPubMed
go back to reference Levy RJ, Johnson TP, Sintov A, Golomb G (1990) Controlled release implants for cardiovascular disease. J Control Release 11:245–254CrossRef Levy RJ, Johnson TP, Sintov A, Golomb G (1990) Controlled release implants for cardiovascular disease. J Control Release 11:245–254CrossRef
go back to reference Levy RJ, Qu X, Underwood T, Trachy J, Schoen FJ (1995) Calcification of valved aortic allografts in rats: effects of age, crosslinking, and inhibitors. J Biomed Mater Res 29:217–226CrossRefPubMed Levy RJ, Qu X, Underwood T, Trachy J, Schoen FJ (1995) Calcification of valved aortic allografts in rats: effects of age, crosslinking, and inhibitors. J Biomed Mater Res 29:217–226CrossRefPubMed
go back to reference Liu X, Wiswall AT, Rutledge JE, Akhter MP, Cullen DM, Reinhardt RA, Wang D (2008) Osteotropic β-cyclodextrin for local bone regeneration. Biomaterials 29:1686–1692CrossRefPubMedPubMedCentral Liu X, Wiswall AT, Rutledge JE, Akhter MP, Cullen DM, Reinhardt RA, Wang D (2008) Osteotropic β-cyclodextrin for local bone regeneration. Biomaterials 29:1686–1692CrossRefPubMedPubMedCentral
go back to reference Lopez PJ, Gautier C, Livage J, Coradin T (2005) Mimicking biogenic silica nanostructures formation. Curr Nanosci 1:73–83CrossRef Lopez PJ, Gautier C, Livage J, Coradin T (2005) Mimicking biogenic silica nanostructures formation. Curr Nanosci 1:73–83CrossRef
go back to reference Luckman SP, Hughes DE, Coxon FP, Graham R, Russell RG, Rogers MJ (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13:581–589CrossRefPubMed Luckman SP, Hughes DE, Coxon FP, Graham R, Russell RG, Rogers MJ (1998) Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 13:581–589CrossRefPubMed
go back to reference Mann S, Perry CC, Williams RJP, Fyfe CA, Gobbi GC, Kennedy GJ (1983) The characterisation of the nature of silica in biological systems. J Chem Soc Chem Commun 4:168–170CrossRef Mann S, Perry CC, Williams RJP, Fyfe CA, Gobbi GC, Kennedy GJ (1983) The characterisation of the nature of silica in biological systems. J Chem Soc Chem Commun 4:168–170CrossRef
go back to reference Martin del Valle EM, Galan MA, Carbonell RG (2009) Drug delivery technologies: the way forward in the new decade. Ind Eng Chem Res 48:2475–2486CrossRef Martin del Valle EM, Galan MA, Carbonell RG (2009) Drug delivery technologies: the way forward in the new decade. Ind Eng Chem Res 48:2475–2486CrossRef
go back to reference Mashkevich BO (ed) (2007) Drug delivery research advances. Nova Science Publishers Inc., New York Mashkevich BO (ed) (2007) Drug delivery research advances. Nova Science Publishers Inc., New York
go back to reference Mestiri M, Benoit JP, Hernigou P, Devissaguet JP, Puisieux F (1995) Cisplatin-loaded poly(methyl methacrylate) implants: a sustained drug delivery system. J Control Release 33:107–113CrossRef Mestiri M, Benoit JP, Hernigou P, Devissaguet JP, Puisieux F (1995) Cisplatin-loaded poly(methyl methacrylate) implants: a sustained drug delivery system. J Control Release 33:107–113CrossRef
go back to reference Morse DE (1999) Silicon biotechnology: harnessing biological silica production to construct new materials. Trends Biotechnol 17:230–232CrossRef Morse DE (1999) Silicon biotechnology: harnessing biological silica production to construct new materials. Trends Biotechnol 17:230–232CrossRef
go back to reference Ning RY (2010) Reactive silica in natural waters—a review. Des Wat Treat 21:79–86CrossRef Ning RY (2010) Reactive silica in natural waters—a review. Des Wat Treat 21:79–86CrossRef
go back to reference Patwardhan SV (2011) Biomimetic and bioinspired silica: recent developments and applications. Chem Commun 47:7567–7582CrossRef Patwardhan SV (2011) Biomimetic and bioinspired silica: recent developments and applications. Chem Commun 47:7567–7582CrossRef
go back to reference Patwardhan SV, Clarson SJ, Perry CC (2005) On the role(s) of additives in bioinspired silicification. Chem Commun 1113–1121 Patwardhan SV, Clarson SJ, Perry CC (2005) On the role(s) of additives in bioinspired silicification. Chem Commun 1113–1121
go back to reference Perry CC, Keeling-Tucker T (1998) Aspects of the bioinorganic chemistry of silicon in conjunction with the biometals calcium, iron and aluminium. J Inorg Biochem 69:181–191CrossRefPubMed Perry CC, Keeling-Tucker T (1998) Aspects of the bioinorganic chemistry of silicon in conjunction with the biometals calcium, iron and aluminium. J Inorg Biochem 69:181–191CrossRefPubMed
go back to reference Ramakrishna S, Mayer J, Wintermantel E, Leong KW (2001) Biomedical applications of polymer-composite materials: a review. Compos Sci Technol 61:1189–1224CrossRef Ramakrishna S, Mayer J, Wintermantel E, Leong KW (2001) Biomedical applications of polymer-composite materials: a review. Compos Sci Technol 61:1189–1224CrossRef
go back to reference Russell RGG, Watts N, Ebetino F, Rogers M (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733–759CrossRefPubMed Russell RGG, Watts N, Ebetino F, Rogers M (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733–759CrossRefPubMed
go back to reference Shakespeare WC, Metcalf CA III, Wang Y, Sundaramoorthi R, Keenan T, Weigele M, Bohacek RS, Dalgarno DC, Sawyer TK (2003) Novel bone-targeted Src tyrosine kinase inhibitor drug discovery. Curr Opin Drug Discov Devel 6:729–741PubMed Shakespeare WC, Metcalf CA III, Wang Y, Sundaramoorthi R, Keenan T, Weigele M, Bohacek RS, Dalgarno DC, Sawyer TK (2003) Novel bone-targeted Src tyrosine kinase inhibitor drug discovery. Curr Opin Drug Discov Devel 6:729–741PubMed
go back to reference Shane E (2010) Evolving data about subtrochanteric fractures and bisphosphonates. N Engl J Med 362:1825–1827CrossRefPubMed Shane E (2010) Evolving data about subtrochanteric fractures and bisphosphonates. N Engl J Med 362:1825–1827CrossRefPubMed
go back to reference Siegel RA, Rathbone MJ (2012) Overview of controlled release mechanisms. In: Siepmann J, Siegel RA, Rathbone MJ (eds) Fundamentals and applications of controlled release drug delivery. Springer, New York, pp 19–43CrossRef Siegel RA, Rathbone MJ (2012) Overview of controlled release mechanisms. In: Siepmann J, Siegel RA, Rathbone MJ (eds) Fundamentals and applications of controlled release drug delivery. Springer, New York, pp 19–43CrossRef
go back to reference Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE (2001) Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 70:1–20CrossRefPubMed Soppimath KS, Aminabhavi TM, Kulkarni AR, Rudzinski WE (2001) Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release 70:1–20CrossRefPubMed
go back to reference Steven CR, Busby GA, Mather C, Tariq B, Lucia Briuglia M, Lamprou DA, Urquhart AJ, Grant MH, Patwardhan SV (2014) Bioinspired silica as drug delivery systems and their biocompatibility. J Mater Chem B 2:5028–5042CrossRefPubMed Steven CR, Busby GA, Mather C, Tariq B, Lucia Briuglia M, Lamprou DA, Urquhart AJ, Grant MH, Patwardhan SV (2014) Bioinspired silica as drug delivery systems and their biocompatibility. J Mater Chem B 2:5028–5042CrossRefPubMed
go back to reference Szymura-Oleksiak J, Slosarczyk A, Cios A, Mycek B, Paszkiewicz Z, Szklarczyk S, Stankiewicz D (2001) The kinetics of pentoxifyllinerelease in vivo from drug-loaded hydroxyapatite implants. Ceram Int 27:767–772CrossRef Szymura-Oleksiak J, Slosarczyk A, Cios A, Mycek B, Paszkiewicz Z, Szklarczyk S, Stankiewicz D (2001) The kinetics of pentoxifyllinerelease in vivo from drug-loaded hydroxyapatite implants. Ceram Int 27:767–772CrossRef
go back to reference Thomas JM, Johnson BFG, Raja R, Samkar G, Midgley PA (2003) High-performance nanocatalysts for single-step hydrogenations. Acc Chem Res 36:20–30CrossRefPubMed Thomas JM, Johnson BFG, Raja R, Samkar G, Midgley PA (2003) High-performance nanocatalysts for single-step hydrogenations. Acc Chem Res 36:20–30CrossRefPubMed
go back to reference Thompson WJ, Thompson DD, Anderson PS, Rodan GA (1989) Polymalonic acids as bone affinity agents. European Patent 0341961 Thompson WJ, Thompson DD, Anderson PS, Rodan GA (1989) Polymalonic acids as bone affinity agents. European Patent 0341961
go back to reference Uhrich KE, Cannizzaro SM, Langer RS, Shakesheff KM (1999) Polymeric systems for controlled drug release. Chem Rev 99:3181–3198CrossRefPubMed Uhrich KE, Cannizzaro SM, Langer RS, Shakesheff KM (1999) Polymeric systems for controlled drug release. Chem Rev 99:3181–3198CrossRefPubMed
go back to reference Van Beek E, Pieterman E, Cohen L, Lowik C, Papapoulos S (1999) Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun 255:491–494CrossRefPubMed Van Beek E, Pieterman E, Cohen L, Lowik C, Papapoulos S (1999) Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun 255:491–494CrossRefPubMed
go back to reference Walcarius A, Etienne M, Lebeau B (2003) Rate of access to the binding sites in organically modified silicates. 2. Ordered mesoporous silicas grafted with amine or thiol groups. Chem Mater 15:2161–2173CrossRef Walcarius A, Etienne M, Lebeau B (2003) Rate of access to the binding sites in organically modified silicates. 2. Ordered mesoporous silicas grafted with amine or thiol groups. Chem Mater 15:2161–2173CrossRef
go back to reference Walter KA, Tamargo R, Olivi A, Burger PC, Brem H (1995) Intratumoral chemotherapy. Neurosurgery 37:1129–1145CrossRef Walter KA, Tamargo R, Olivi A, Burger PC, Brem H (1995) Intratumoral chemotherapy. Neurosurgery 37:1129–1145CrossRef
go back to reference Wang GH, Zhang LM (2007) Manipulating formation and drug-release behavior of new sol-gel silica matrix by hydroxypropyl guar gum. J Phys Chem B 111:10665–10670CrossRefPubMed Wang GH, Zhang LM (2007) Manipulating formation and drug-release behavior of new sol-gel silica matrix by hydroxypropyl guar gum. J Phys Chem B 111:10665–10670CrossRefPubMed
go back to reference Zhao Z-G (1992) Adsorption of phenylalanine from aqueous solution onto active carbon and silica gel. Chin J Chem 10:325–330CrossRef Zhao Z-G (1992) Adsorption of phenylalanine from aqueous solution onto active carbon and silica gel. Chin J Chem 10:325–330CrossRef
Metadata
Title
Silica-Based Polymeric Gels as Platforms for Delivery of Phosphonate Pharmaceutics
Authors
Konstantinos E. Papathanasiou
Maria Vassaki
Argyro Spinthaki
Argyri Moschona
Konstantinos D. Demadis
Copyright Year
2018
Publisher
Springer Singapore
DOI
https://doi.org/10.1007/978-981-10-6083-0_5

Premium Partners